ArticleRadiation oncology (London, England)2025
Impact of frailty on outcomes of inpatient stereotactic radiosurgery for brain metastasis: a national readmission database analysis 2016-2020.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is not clear how frailty may affect the outcomes of stereotactic radiosurgery (SRS) for brain metastasis. This study aimed to evaluate the impact of frailty on clinical outcomes in patients ≥ 60 years old who underwent SRS for brain metastasis from a population-based perspective. MATERIALS AND
methodsData were extracted from the National Readmission Database (NRD), 2016 to 2020. Inclusion criteria were ≥ 60 years old with brain metastasis who underwent SRS. Frailty was assessed using the modified Frailty Index (mFI), derived from 11 clinical conditions. The primary outcomes were in-hospital mortality, length of hospital stay (LOS), total hospital costs, and 30-day and 90-day readmission rates. Logistic and linear regression models were used to assess the association between frailty and outcomes.
resultsA total of 904 patients (mean age: 71 years, 53% male) were included, of which 17.5% were defined as frail. After adjusting for demographic, clinical, and hospital-related factors, frailty was significantly associated with increased in-hospital mortality (adjusted odds ratio [aOR] = 2.39, 95% confidence interval [CI]: 1.16-4.92), longer LOS (adjusted Beta [aBeta] = 2.61 days, 95% CI: 1.95-3.28), higher total costs (aBeta = $36.04 thousand USD, 95% CI: 28.84-43.23), and higher 30-day readmission rate (aOR = 1.47, 95% CI: 1.02-2.11).
conclusionFrailty independently predicts poorer outcomes in older adults undergoing SRS for brain metastasis, including higher mortality, longer hospital stays, increased hospital costs, and increased 30-day readmission rate. These findings highlight the importance of incorporating frailty-informed risk stratification and perioperative care planning to optimize patient outcomes. TRIAL REGISTRATION NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.